All Outputs (6)

EGFR and related therapeutic targets in malignant pleural mesothelioma (2016)
Thesis
Oguh, L. I. (2016). EGFR and related therapeutic targets in malignant pleural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4221787

Introduction
Malignant pleural mesothelioma (MPM) is a rare but aggressive disease and the current first line treatment is associated with a survival rate of 40%. There is currently no second line therapy. This study aimed to explore the expression... Read More about EGFR and related therapeutic targets in malignant pleural mesothelioma.

Proteomic identification of putative biomarkers of radiotherapy resistance (2012)
Thesis
Scaife, L. (2012). Proteomic identification of putative biomarkers of radiotherapy resistance. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4214086

Background
Currently, tumour response to radiotherapy cannot be predicted meaning that those patients with tumours resistant to the therapy endure the harmful side effects associated with ionising radiation in the absence of therapeutic gain. The ai... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance.

Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer (2012)
Thesis
ElFadl, D. (2012). Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4218629

Background:
Breast cancer is an important health issue. The majority of patients present with early stage cancer and are therefore candidates for breast conserving surgery and radiotherapy. A proportion will suffer from local recurrence, which may b... Read More about Proteomic identification and validation of biomarkers associated with resistance to radiotherapy in breast cancer.

The significance of the EGFR pathway in malignant pleural mesothelioma (2012)
Thesis
Agarwal, V. (. (2012). The significance of the EGFR pathway in malignant pleural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4214047

Introduction
EGFR, MTOR and COX2 are up regulated in malignant pleural mesothelioma (MPM). In this study we aimed to determine the expression of Lipoxygenase enzymes (LOX), absence of PTEN protein expression and the cytotoxic effect of EGFR, MTOR an... Read More about The significance of the EGFR pathway in malignant pleural mesothelioma.

The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics (2011)
Thesis
Hodgkinson, V. C. (2011). The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4211852

Background:Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for locally advanced breast cancer. The ability to predict tumour response would allow chemotherapy administration to be directed towards only those patients wh... Read More about The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics.

The proteomic analysis of resistance to anticancer therapy in human breast cancer (2006)
Thesis
Smith, L. (2006). The proteomic analysis of resistance to anticancer therapy in human breast cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4212607

Resistance to anticancer therapy represents a major barrier in the successful management of human breast cancer. The identification of novel biomarkers that correlate with treatment response would increase our understanding of the resistance mechanis... Read More about The proteomic analysis of resistance to anticancer therapy in human breast cancer.